Skip to main content
SpringerLink
Log in

Novantrone for childhood malignant solid tumors

A pediatric oncology group Phase II study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

One hundred one patients with advanced pediatric malignant solid tumors, refractory to conventional chemotherapy, were given Novantrone in a Phase II study. A dosage of 18 mg/m2 was administered as a short intravenous infusion every 3 weeks. One complete and 2 partial responses were observed among 26 patients treated for rhabdomyosarcoma; one of 22 patients with neuroblastoma developed a partial response. Nausea and vomiting were uncommon. Leukopenia and/or granulocytopenia developed in 90 of 98 evaluable entries. Two patients developed fatal congestive heart failure, which may have been related to the fact that these patients previously had received doxorubicin; 3 other patients developed evidence of changes in cardiac function, without congestive heart failure. Evidence of activity of this agent in patients who had previously received doxorubicin suggests that Novantrone should be evaluated in pediatric subjects with malignant solid tumors who have had no prior exposure to anthracyclines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Johnson RK, Zee-Cheng RKY, Lee WW: Experimental antitumor activity of aminoanthroquinones. Cancer Treat Rep 63:425–439, 1979

    Google Scholar 

  2. Cheng CC, Zbinden G, Zee-Cheng RKY: Comparison of antineoplastic activity of aminoethyl anthroquinones and anthracycline antibiotics. J Pharm Sci 68:393–396, 1979

    Google Scholar 

  3. Wallace RE, Murdock KC, Angier RB, Durr PE: Activity of a novel anthracenedione, 1, 4-dihydroxy-5,8-bis(((2-((2- hydroxyethyl)amino)ethyl)-amino))-9, 10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:1570–1574, 1979

    Google Scholar 

  4. Smith IE: Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10:103–115, 1983

    Google Scholar 

  5. Von Hoff DD, Coltman CA, Forseth B: Activity of Mitoxantrone in a human tumor cloning system. Cancer Res 41:1853–1855, 1981

    Google Scholar 

  6. Von Hoff DD, Pollard E, Kuhn J: Phase I clinical investigation of 1,4-dihydroxy-5,8-bis(((2-((2-hydroxyethyl)-amino)) -9,10, anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516–1518, 1980

    Google Scholar 

  7. Alberts DS, Griffith KS, Goodman GE, Herman TS, Murray E: Phase I clinical trial of Mitoxantrone: a new anthracenedione anticancer drugs. Cancer Chemother Pharmacol 5:11–15, 1980

    Google Scholar 

  8. Goldsmith MA, Ohnuma T, Roboz J, Jaffrey I, Greenspan EM, Holland JF: Phase I clinical and pharmacological evaluation of mitoxantrone (Abstract). Proc Am Assoc Cancer Res 22:389, 1981

    Google Scholar 

  9. Wynert W, Harvey H, Lipton A, Schweitzer J, White D: Phase I Study of dihydroxyanthracenedione (Mitoxantrone) (Abstract). Proc Am Assoc Cancer Res 22:352, 1981

    Google Scholar 

  10. Vietti TJ, Steuber CP, Kim TH, Holcenberg J, Kamen B, Murray E, Capiello V: Mitoxantrone in children with advanced malignant disease. In M Rozencweig, DD Von Hoff and MJ Staquet (eds): New Anticancer Drugs: Mitoxantrone and Bisantrene. Raven Press, New York, 1983, pp 93–102

    Google Scholar 

  11. Leyden M, Cheng ZM, Collins J, Russell I, Andrews J, Sullivan J: Mitoxantrone treatment in advanced breast cancer. Aust NZ J Surg 54:21–24, 1984

    Google Scholar 

  12. Neidhart JA, Gochnour D, Roach RW, Young D, Steinberg JA: A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. Semin Oncol 11(Suppl 1):11–14, 1984

    Google Scholar 

  13. Crossley RJ: Clinical safety and tolerance of mitoxantrone. Semin Oncol 11(Suppl 1):54–58, 1984

    Google Scholar 

  14. Moore JO, Olsen GA: Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11(Suppl 1):41–46, 1984

    Google Scholar 

  15. Paciucci PA, Cuttner J, Holland JF: Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11(Suppl 1):36–40, 1984

    Google Scholar 

  16. Prentice HG, Robbins G, Ma DD, Ho AD: Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11(Suppl 1):32–35, 1984

    Google Scholar 

  17. Ungerleider RS, Pratt CB, Vietti TJ, Holcenberg JS, Kamen BA, Glaubiger DL, Cohen LF: Phase I Trial of mitoxantrone in children. Cancer Treat Rep 69:403–407, 1985.

    Google Scholar 

  18. Glaubiger DL, Von Hoff DD, Holcenberg JS, Kamen B, Pratt CB, Ungerleider RS: The relative tolerance of children and adults to anticancer drugs. Front Radiat Ther Oncol 16:42–49, 1981

    Google Scholar 

  19. Vietti TJ: Evaluation of toxicity: Clinical Issues. Cancer Treat Rep 64:457–461, 1980

    Google Scholar 

  20. Pratt CB, Crom DB, Wallenberg J, Sanyal SK, Miliauskas J, Sohlberg K: Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. Cancer Treat Rep 67:85–88, 1983

    Google Scholar 

  21. Adriamycin induced myocardial lesions. Report of a Workshop. Am J Surg Pathol 1:55–60, 1977

    Google Scholar 

  22. Foster BJ, Lev L, Bergemann L, Marsoni S: Cardiac events in Phase II trials with Mitoxantrone. Cancer Treat Symp 3:43–46, 1984

    Google Scholar 

  23. Ungerferth DV, Bashore TM, Magorien RD, Fetters J, Neidhart JA: Histologic and functional characteristics of human heart after Mitoxantrone therapy. Cancer Treat Symp 3:47–53, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Jude Children's Research Hospital, USA

    C. B. Pratt M.D.

  2. Washington University School of Medicine, USA

    T. J. Vietti

  3. St. Jude Children's Research Hospital, USA

    E. Etcubanas

  4. Oklahoma University Health Sciences Center, USA

    C. Sexauer

  5. City of Hope National Medical Center, USA

    R. A. Krance

  6. Baylor College of Medicine, USA

    D. H. Mahoney

  7. Bowman Gray School of medicine, USA

    R. B. Patterson

Authors
  1. C. B. Pratt M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. J. Vietti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Etcubanas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Sexauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. A. Krance
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. H. Mahoney
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. B. Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pratt, C.B., Vietti, T.J., Etcubanas, E. et al. Novantrone for childhood malignant solid tumors. Invest New Drugs 4, 43–48 (1986). https://doi.org/10.1007/BF00172015

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172015

Key words

Search

Navigation